Page 12 - Read Online

Page 6 of 7 Örmeci. Hepatoma Res 2019;5:11 I http://dx.doi.org/10.20517/2394-5079.2019.14

Financial support and sponsorship
None.

Conflicts of interest
Author declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Conti F, Bionfiglioli F, Scuteri A, Crespi C, Bolondi L, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-
related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727-33.
2. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, et al. Sustained virologic response and clinical outcomes in patients
with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677-84.
3. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, et al. Eradication of hepatitis C virüs infection and the development of
hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158:329-37.
4. El-Seraq HB., Kanwal F., Richardson P., Kramer J. Risk of hepatocellular carcinoma after sustained virological response in Veterans
with hepatitis C virus infection. Hepatology 2016;64:130-7.
5. Nault JC, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments:Controversy after the revolution. J Hepatol
2016;65:663-5.
6. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, et al. Randomised trial of effects of interferon-α on incidence of
hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5.
7. Reig M, Marino Z, Perello C, Inarrairaegui M, Ribeiro A, et al. Unexpected high rate of early tumour recurrence in patients with HCV-
related HCC undergoing interferon-free therapy. J Hepatol 2016;65:719-26.
8. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, et al. Eradication of hepatitis C virus infection and the development of
hepatocellular carcinoma. Ann Intern Med 2013;158:329-37.
9. Ravi S, Axley P, Jones D, Kodali S, Simpson H, et al. Unusually high rates of hepatocellular carcinoma after treatment with direct-
acting antiviral therapy for hepatitis C related cirrhosis. Gastroenterology 2017;152:911-3.
10. Cardoso H, Vale AM, Rodrigues S, Gonçalves R, Albuquerque A, et al. High incidence of hepatocellular carcinoma following
successful interferon-free antiviral therapy for hepatitis C associated cirrhosis. J Hepatol 2016;65:1057-71.
11. Yang JD, Agel BA, Pungpapong S, Gores GJ, Roberts LR. Direct acting antiviral therapy and tumour recurrence after liver
transplantation for hepatitis C-associated hepatocellular carcinoma. J Hepatol 2016;65;856-68.
12. Beste LA, Green PK, Berry K, Kogut MJ, Allison S, et al. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran
patients with hepatocellular carcinoma. J Hepatol 2017;67:32-9.
13. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, et al. Interferon therapy reduces the risk for hepatocellular carcinoma:
national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of
Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999;131:174-81.
14. Moon C, Jung KS, Kim DY, Baatarkhuu O, Park JY, et al. Lower incidence of hepatocelluler carcinoma and cirrhosis in hepatitis C
patients with sustained virological response by pegylated interferon and ribavirin. Dig Dis Sci 2015;60:573-81.
15. Innes H, Barclay ST, Hayes PC, Fraser A, Dillon JF, et al. The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C
and sustained viral response: role of the treatment regimen. J Hepatol 2018;68:646-54.
16. Telep LE, Muramoto D, Osinusi A, Brainard DM, Reddy KR, et al. No ıncreased risk of hepatocellular carcinoma recurrence in
patients following interferon-free, direct acting anti-viral treatment for hepatitis C virus: a cohort study using large-scale administrative
medical claims data. J Hepatol 2017;66:S333-542.
17. Li DK, Ren Y, Fierer DS, Rutledge S, Shaikh OS, et al. The short-term incidence of hepatocellular carcinoma is not increased after
hepatitis C treatment with Direct-acting antivirals: an ERCHIVES study. Hepatology 2018;67:2244-53.
18. Petta S, Cabibbo G, Barbara M, Attardo S, Bucci L, et al. Hepatocellular carcinoma recurrence in patients with curative resection or
ablation: impact of HCV eradication does not depend on the use of interferon. Aliment Pharmacol Ther 2017;45:160-8.
19. Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavo MR, et al. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic
patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Aliment Pharmacol Ther 2017;46:688-95.
20. Virlogeux V, Pradat P, Hartig-Lavie K, Bailly F, Maynard M, et al. Direct-acting antiviral therapy decreases hepatocellular carcinoma
recurrence rate in cirrhotic patients with chronic hepatitis C. Liver International 2017;37:1122-7.
21. Mettke F, Schlevogt B, Deterding K, Wranke A, Smith A, et al. Interferon-free therapy of chronic hepatitis C with direct-acting